Skip to contentC
Cytosorbents Corp
C
CTSOCytosorbents Corp Q2 2024 · 10-Q
Revenue$8.84M$8.84M−6.1% vs Q2 2023 Net Income-$4.29M-$4.29MN/M vs Q2 2023 EPS Diluted-$0.08-$0.08N/M vs Q2 2023 Gross Profit$6,503,000+8.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytosorbents Corp · CIK 1175151 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,794,241N/M Free Cash Flowderived-$4,812,050N/M Margins · derivedGross margin73.5%+9.7 pt vs Q2 2023
Operating margin-40.4%+29.2 pt vs Q2 2023
Net margin-48.6%+16.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end